Skip to main content
Medical information Clinical review pending

Genetic Testing

NPM1 Mutation Analysis Exon 12 Insertion

Detects specific genetic mutations in the NPM1 gene, often linked to acute myeloid leukemia (AML) and other blood disorders. This test helps guide diagnosis and treatment.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Bone marrow aspirate or peripheral blood collected in an EDTA Vacutainer tube (2ml). Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. However, a doctor's prescription is necessary to order this test.
Test priceKSh 12,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the NPM1 Mutation Analysis Exon 12 Insertion test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of acute myeloid leukemia (AML)
  • ✓Prognosis assessment in AML
  • ✓Guiding treatment decisions for AML
  • ✓Investigating unexplained blood count abnormalities
  • ✓Family history of hematological disorders
02

In plain language

What this test helps you understand

This test helps identify specific genetic mutations associated with certain blood cancers, particularly AML. The results can aid in confirming a diagnosis, predicting prognosis, and guiding treatment decisions.
The NPM1 Mutation Analysis Exon 12 Insertion test identifies mutations within the NPM1 gene. These mutations are frequently associated with acute myeloid leukemia (AML) and other hematological conditions. Understanding the presence of these mutations is important for diagnosis, prognosis, and tailoring treatment strategies. This test analyzes genetic material from a blood or bone marrow sample to detect specific insertions in exon 12 of the NPM1 gene. Early detection can lead to more effective management and improved patient outcomes. Discuss with your doctor if this test is appropriate for you.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. However, a doctor's prescription is necessary to order this test.
SampleBone marrow aspirate or peripheral blood collected in an EDTA Vacutainer tube (2ml). Confirm specific requirements with the laboratory before booking.
MethodologyMolecular genetic analysis, typically using techniques like PCR (Polymerase Chain Reaction) and sequencing or specific mutation detection assays.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically looks for insertions in exon 12 of the NPM1 gene. It does not detect other types of mutations or genetic abnormalities. Results must be interpreted in the context of the patient's overall clinical picture. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The NPM1 gene provides instructions for making a protein involved in cell growth and division. Mutations in this gene can contribute to the development of certain cancers, particularly AML.
NPM1 mutations are common in AML and can affect prognosis and response to treatment. Identifying these mutations helps doctors choose the most effective therapy.
The test requires either a bone marrow sample or a peripheral blood sample collected in a specific type of tube (EDTA Vacutainer).
A positive result indicates the presence of the specific NPM1 mutation being tested for. Your doctor will interpret the results in the context of your medical history and other test findings.
Yes, a doctor's prescription or referral is required to order this genetic test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp